MX2017014001A - Analogos de nucleosidos 5 ' -sustituidos. - Google Patents

Analogos de nucleosidos 5 ' -sustituidos.

Info

Publication number
MX2017014001A
MX2017014001A MX2017014001A MX2017014001A MX2017014001A MX 2017014001 A MX2017014001 A MX 2017014001A MX 2017014001 A MX2017014001 A MX 2017014001A MX 2017014001 A MX2017014001 A MX 2017014001A MX 2017014001 A MX2017014001 A MX 2017014001A
Authority
MX
Mexico
Prior art keywords
cancer
compounds
substituted nucleoside
nucleoside analogs
cholangiocarcinoma
Prior art date
Application number
MX2017014001A
Other languages
English (en)
Inventor
Andrew Woods Timothy
Morgan Watson Brian
S Cortez Guillermo
Quyoom Bonday Zahid
Robert Dahnke Karl
John Grogan Michael
Rodriguez Hergueta Antonio
Andrew Jamison James
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2017014001A publication Critical patent/MX2017014001A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de nucleósidos. 5'-sustituidos novedosos, composiciones farmacéuticas que comprenden los compuestos y métodos de utilización de los compuestos para tratar el cáncer, más particularmente para el tratamiento del cáncer, en particular los glioblastomas, melanoma, sarcomas, cáncer gástrico, cáncer de páncreas, colangiocarcinoma, cáncer de vejiga, cáncer de mama, cáncer de pulmón de células no pequeñas, leucemias, incluyendo leucemia mieloide aguda y los linfomas.
MX2017014001A 2015-05-04 2016-04-27 Analogos de nucleosidos 5 ' -sustituidos. MX2017014001A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382225 2015-05-04
PCT/US2016/029475 WO2016178870A1 (en) 2015-05-04 2016-04-27 5'-substituted nucleoside analogs

Publications (1)

Publication Number Publication Date
MX2017014001A true MX2017014001A (es) 2018-03-16

Family

ID=53177322

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014001A MX2017014001A (es) 2015-05-04 2016-04-27 Analogos de nucleosidos 5 ' -sustituidos.

Country Status (25)

Country Link
US (1) US9840532B2 (es)
EP (1) EP3292128A1 (es)
JP (2) JP6181889B1 (es)
KR (1) KR20170132871A (es)
CN (1) CN107580602A (es)
AR (1) AR104326A1 (es)
AU (1) AU2016258485A1 (es)
BR (1) BR112017020336A2 (es)
CA (1) CA2981097A1 (es)
CL (1) CL2017002637A1 (es)
CO (1) CO2017010727A2 (es)
CR (1) CR20170443A (es)
DO (1) DOP2017000255A (es)
EA (1) EA201792169A1 (es)
EC (1) ECSP17072987A (es)
HK (1) HK1244007A1 (es)
IL (1) IL254409A0 (es)
MA (1) MA42036A (es)
MX (1) MX2017014001A (es)
PE (1) PE20180231A1 (es)
PH (1) PH12017502002A1 (es)
SG (1) SG11201708345XA (es)
TN (1) TN2017000459A1 (es)
TW (1) TWI615400B (es)
WO (1) WO2016178870A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017010844A (es) * 2015-02-24 2017-12-07 Pfizer Derivados de nucleosidos sustituidos utiles como agentes anticancerosos.
JP7043080B2 (ja) * 2017-01-27 2022-03-29 国立大学法人 宮崎大学 がんに対する有効性判定キット及びがんに対する有効性判定方法
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152548A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
ES2885180T3 (es) * 2017-08-09 2021-12-13 Prelude Therapeutics Inc Inhibidores selectivos de la proteína arginina metiltransferasa 5 (PRMT5)
CN111542525B (zh) * 2017-10-26 2023-06-27 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
US11459330B2 (en) 2017-12-13 2022-10-04 Lupin Limited Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
JP7328241B2 (ja) * 2018-03-14 2023-08-16 プレリュード セラピューティクス，インコーポレイティド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
WO2020033285A1 (en) * 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CN113811539A (zh) * 2019-02-13 2021-12-17 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
JP2022536337A (ja) 2019-06-10 2022-08-15 ルピン・リミテッド Ｐｒｍｔ５阻害剤
CA3156135A1 (en) 2019-10-22 2021-04-29 Lupin Limited PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITORS
JP2023504279A (ja) 2019-12-03 2023-02-02 ルピン・リミテッド Ｐｒｍｔ５阻害剤としての置換ヌクレオシドアナログ
GB202117230D0 (en) 2021-11-29 2022-01-12 Argonaut Therapeutics Ltd Peptide vaccine
GB202203588D0 (en) 2022-03-15 2022-04-27 Argonaut Therapeutics Ltd Cancer diagnostic
CN116211869B (zh) * 2022-12-07 2023-08-01 浙江省肿瘤医院 含dna损伤修复抑制剂的药物混合物及混合方法、用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511454A (ja) 1999-08-27 2003-03-25 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド ピロロ［２，３−ｄ］ピリミジンヌクレオシド類似化合物
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
WO2011079236A1 (en) 2009-12-22 2011-06-30 The Ohio State University Research Foundation Compositions and methods for cancer detection and treatment
WO2013009735A1 (en) 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
DK2935222T3 (en) 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
CA2899363A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
JP2016511744A (ja) 2012-12-21 2016-04-21 エピザイム，インコーポレイティド Ｐｒｍｔ５を阻害する方法
WO2014100734A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
MX2017010844A (es) 2015-02-24 2017-12-07 Pfizer Derivados de nucleosidos sustituidos utiles como agentes anticancerosos.

Also Published As

Publication number Publication date
TW201712022A (zh) 2017-04-01
AU2016258485A1 (en) 2017-10-12
ECSP17072987A (es) 2018-02-28
JP2017125029A (ja) 2017-07-20
MA42036A (fr) 2018-03-14
PH12017502002A1 (en) 2018-03-26
CO2017010727A2 (es) 2018-01-31
CN107580602A (zh) 2018-01-12
TWI615400B (zh) 2018-02-21
DOP2017000255A (es) 2018-01-15
AR104326A1 (es) 2017-07-12
JP2017525667A (ja) 2017-09-07
CA2981097A1 (en) 2016-11-10
KR20170132871A (ko) 2017-12-04
US20160326208A1 (en) 2016-11-10
PE20180231A1 (es) 2018-01-31
WO2016178870A1 (en) 2016-11-10
IL254409A0 (en) 2017-11-30
CR20170443A (es) 2017-11-07
HK1244007A1 (zh) 2018-07-27
SG11201708345XA (en) 2017-11-29
JP6181889B1 (ja) 2017-08-16
EP3292128A1 (en) 2018-03-14
EA201792169A1 (ru) 2018-03-30
TN2017000459A1 (en) 2019-04-12
US9840532B2 (en) 2017-12-12
BR112017020336A2 (pt) 2019-05-14
CL2017002637A1 (es) 2018-04-20

Similar Documents

Publication Publication Date Title
PH12017502002A1 (en) 5`-substituted nucleoside analogs
MX2022014648A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
PH12019501959A1 (en) Therapeutic rna
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
NZ734594A (en) Bicyclic heterocycles as fgfr4 inhibitors
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
EA024630B9 (ru) Производные пиразола как ингибиторы ионных каналов, активируемых высвобождением кальция (crac)
MX2022012013A (es) Composiciones y metodos para transduccion de tumores.
MX2019010039A (es) Composiciones y métodos para transducción de tumores.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
UA119458C2 (uk) Сполуки піридину пладієноліду та способи застосування
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2018011046A (es) Composiciones y metodos para tratar canceres.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
MX2018002304A (es) Composiciones minerales para la estimulacion del metabolismo de los hidratos de carbono.
GEP20197007B (en) Therapeutic agent for frontal lobe dysfunction
MX2017013669A (es) Composiciones para el tramiento del cancer.